| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/073738WO2015063339A1 (en) | 2013-11-04 | 2014-11-04 | Production of t cell retargeting hetero-dimeric immunoglobulins |
| EP15167034 | 2015-05-08 |
| Publication Number | Publication Date |
|---|---|
| MA40894Atrue MA40894A (en) | 2017-09-12 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040894AMA40894A (en) | 2014-11-04 | 2015-11-02 | HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES |
| Country | Link |
|---|---|
| EP (1) | EP3215541A1 (en) |
| JP (3) | JP2018501297A (en) |
| KR (1) | KR102760422B1 (en) |
| CN (1) | CN107207596A (en) |
| AU (1) | AU2015341884B2 (en) |
| BR (1) | BR112017009263A2 (en) |
| CA (1) | CA2965745C (en) |
| CL (1) | CL2017001090A1 (en) |
| CO (1) | CO2017005240A2 (en) |
| EA (1) | EA039658B1 (en) |
| HK (1) | HK1244014A1 (en) |
| IL (1) | IL251848A0 (en) |
| MA (1) | MA40894A (en) |
| MX (1) | MX2017005814A (en) |
| MY (1) | MY186929A (en) |
| NZ (1) | NZ732019A (en) |
| PE (1) | PE20171041A1 (en) |
| PH (1) | PH12017500819A1 (en) |
| SG (1) | SG11201703313SA (en) |
| WO (1) | WO2016071355A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| DK2943511T3 (en) | 2013-01-14 | 2019-10-21 | Xencor Inc | NEW HETERODIMERIC PROTEINS |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| RS63152B1 (en) | 2013-07-25 | 2022-05-31 | Cytomx Therapeutics Inc | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| EA036577B1 (en) | 2013-11-04 | 2020-11-25 | Икнос Сайенсиз Са | Production of t cell retargeting hetero-dimeric immunoglobulins |
| BR112016022385A2 (en) | 2014-03-28 | 2018-06-19 | Xencor, Inc | specific antibodies that bind to cd38 and cd3 |
| EP3172235A2 (en)* | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| EA037065B1 (en) | 2014-11-26 | 2021-02-01 | Ксенкор, Инк. | Heterodimeric antibodies that bind cd3 and cd38 |
| ES2886523T3 (en) | 2014-11-26 | 2021-12-20 | Xencor Inc | Heterodimeric antibodies that bind to CD3 and CD20 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for msln and cd3 |
| TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for flt3 and cd3 |
| TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for egfrviii and cd3 |
| AU2016365742A1 (en) | 2015-12-07 | 2018-06-21 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
| DK3411404T3 (en) | 2016-02-03 | 2023-01-30 | Amgen Res Munich Gmbh | PSMA-AND CD3-BISPECIFIC T CELL-ENGINEERING ANTIBODY CONSTRUCTS |
| EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
| HUE068801T2 (en) | 2016-06-14 | 2025-01-28 | Xencor Inc | Bispecific checkpoint inhibitor antibodies |
| CN109715663B (en) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | Heterodimeric antibodies binding to somatostatin receptor 2 |
| JP2020517659A (en)* | 2017-04-24 | 2020-06-18 | イクノス サイエンシズ エスエー | T cell redirected bispecific antibody for treatment of EGFR positive cancer |
| WO2018224441A1 (en)* | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| JP7247110B2 (en) | 2017-06-05 | 2023-03-28 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | Novel anti-CD3 antibody |
| CN110997722B (en)* | 2017-06-08 | 2023-09-26 | 黑带医疗有限公司 | CD38 modulating antibodies |
| JP7679196B2 (en) | 2017-06-08 | 2025-05-19 | ブラック ベルト セラピューティクス リミテッド | CD38 regulatory antibody |
| ES2911243T3 (en) | 2017-08-10 | 2022-05-18 | Grifols Diagnostic Solutions Inc | Compositions, methods and/or kits comprising a recombinant extracellular domain of human cd38 |
| EP3668896A1 (en) | 2017-08-16 | 2020-06-24 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
| CN111032086B (en) | 2017-08-16 | 2023-09-26 | 黑带医疗有限公司 | CD38 antibodies |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| AU2018347607B2 (en) | 2017-10-14 | 2025-08-21 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| EP3706793A1 (en) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| EP3773911A2 (en) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| WO2020064865A1 (en)* | 2018-09-25 | 2020-04-02 | Ichnos Sciences S.A. | Antibody quantification in biological samples |
| KR102353568B1 (en) | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | Anti c-Met Antibody or Antigen binding fragment thereof with Improved Stability |
| CN113614107A (en)* | 2019-01-23 | 2021-11-05 | Encefa公司 | CD31 competitors and uses thereof |
| US20220177582A1 (en)* | 2019-03-13 | 2022-06-09 | Ichnos Sciences SA | Non-consensus glycosylation of bispecific antibodies |
| MX2021014193A (en)* | 2019-05-23 | 2022-01-06 | Velosbio Inc | Anti-ror1/anti-cd3 bispecific binding molecules. |
| JP7684656B2 (en)* | 2019-06-11 | 2025-05-28 | 小野薬品工業株式会社 | Immunosuppressants |
| CN110551222B (en)* | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | A novel bifunctional antibody and its application |
| CN112538114B (en)* | 2019-09-20 | 2025-05-02 | 上海普铭生物科技有限公司 | Anti-human CD38 antibody and its application |
| EP4039707A4 (en)* | 2019-09-30 | 2022-11-16 | Harbour Biomed (Shanghai) Co., Ltd | CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND USE THEREOF |
| CN113493519B (en)* | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | Fusion protein with remarkably prolonged half-life for treating ocular angiogenesis diseases |
| WO2021185001A1 (en) | 2020-03-19 | 2021-09-23 | 深圳纽迪瑞科技开发有限公司 | Strain sensing film, pressure sensor and hybrid strain sensing system |
| CN115803340A (en)* | 2020-04-24 | 2023-03-14 | 纪念斯隆凯特琳癌症中心 | Anti-CD3 antibodies and uses thereof |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CA3180690A1 (en)* | 2020-06-17 | 2021-12-23 | Ahmed Mahiuddin | Cd38 antibodies for treatment of human diseases |
| JP2023538891A (en) | 2020-08-19 | 2023-09-12 | ゼンコア インコーポレイテッド | Anti-CD28 composition |
| WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| EP4380631A4 (en)* | 2021-08-04 | 2025-06-25 | Abpro Corporation | Antibodies directed against CD3 and their uses |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54056B1 (en)* | 2004-02-06 | 2015-10-30 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
| SG10201912554TA (en)* | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| DK2860192T3 (en)* | 2005-10-12 | 2018-01-02 | Morphosys Ag | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| EP1914242A1 (en)* | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| PL2975051T3 (en)* | 2009-06-26 | 2021-09-20 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| PL2522724T3 (en)* | 2009-12-25 | 2020-07-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide modification method for purifying polypeptide multimers |
| DK2580243T3 (en)* | 2010-06-09 | 2020-01-13 | Genmab As | ANTIBODIES AGAINST HUMAN CD38 |
| JOP20210044A1 (en)* | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-CD38 . antibody |
| EA201791693A1 (en)* | 2011-03-25 | 2018-05-31 | Гленмарк Фармасьютикалс С.А. | HETERODIMERNY IMMUNOHLOBULINS |
| EP3401337A1 (en)* | 2012-09-25 | 2018-11-14 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| US9486547B2 (en)* | 2012-11-05 | 2016-11-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
| EA036577B1 (en)* | 2013-11-04 | 2020-11-25 | Икнос Сайенсиз Са | Production of t cell retargeting hetero-dimeric immunoglobulins |
| Publication number | Publication date |
|---|---|
| WO2016071355A1 (en) | 2016-05-12 |
| MX2017005814A (en) | 2017-08-02 |
| CA2965745C (en) | 2023-12-05 |
| CA2965745A1 (en) | 2016-05-12 |
| PE20171041A1 (en) | 2017-07-19 |
| CL2017001090A1 (en) | 2018-01-05 |
| MY186929A (en) | 2021-08-26 |
| SG11201703313SA (en) | 2017-05-30 |
| BR112017009263A2 (en) | 2018-01-30 |
| JP2021184722A (en) | 2021-12-09 |
| EA201790961A1 (en) | 2017-10-31 |
| CO2017005240A2 (en) | 2017-10-31 |
| KR102760422B1 (en) | 2025-02-03 |
| JP7403505B2 (en) | 2023-12-22 |
| EA039658B1 (en) | 2022-02-22 |
| JP2018501297A (en) | 2018-01-18 |
| AU2015341884B2 (en) | 2020-09-17 |
| CN107207596A (en) | 2017-09-26 |
| HK1244014A1 (en) | 2018-07-27 |
| AU2015341884A1 (en) | 2017-06-08 |
| JP2019214582A (en) | 2019-12-19 |
| PH12017500819A1 (en) | 2017-10-02 |
| EP3215541A1 (en) | 2017-09-13 |
| KR20170078831A (en) | 2017-07-07 |
| NZ732019A (en) | 2022-07-29 |
| IL251848A0 (en) | 2017-06-29 |
| Publication | Publication Date | Title |
|---|---|---|
| MA40894A (en) | HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES | |
| HUS2500002I1 (en) | Novel anti-pd-l1 antibodies | |
| IL252467A0 (en) | Heterodimeric antibodies that bind cd3 and cd38 | |
| IL255727A (en) | Novel anti-pd-l1 antibodies | |
| IL248007A0 (en) | Bispecific antibodies that bind to cd38 and cd3 | |
| EP3397263A4 (en) | PROCESSES FOR PRODUCING T CELLS AND LYMPHOCYTES AS PRODUCED | |
| MA40889A (en) | HEREODIMERIC IMMUNOGLOBULINS RE-TARGET LYMPHOCYTES | |
| SG10201603721TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201705552QA (en) | Anti-pd-l1 antibodies | |
| EP3341485A4 (en) | ENHANCED PRODUCTION OF IMMUNOGLOBULINS | |
| MA41375A (en) | BISPECIFIC IGG ANTIBODIES AND THEIR PREPARATION PROCESSES | |
| MA42829A (en) | COMPOSITIONS DERIVED FROM PLACENTA AND PROCESSES FOR PRODUCING THEM | |
| MA39915A (en) | PLADIENOLIDE PYRIDINE COMPOUNDS AND PROCESSES FOR USE | |
| EP3515503A4 (en) | MANIPULATED LYMPHOCYTES | |
| FI20155385A7 (en) | Methods for the continuous production of products from microorganisms | |
| HUE059655T2 (en) | Novel anti-human GPVI antibodies and their uses | |
| MA44517A (en) | RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND PROCESSES FOR PRODUCTION AND USE | |
| EP3154360C0 (en) | DAIRY PRODUCTS AND THEIR PRODUCTION PROCESSES | |
| MA45831A (en) | BED ANTI-BODY MONOCLONAL ANTIBODIES AND THEIR PRODUCTION AND USE PROCESSES | |
| EP3486236A4 (en) | SYNTHESIS PROCESS AND INTERMEDIATE PRODUCT FOR PROTHIOCONAZOLE AND ENANTIOMES THEREOF | |
| EP3340979A4 (en) | COMPOSITIONS AND METHODS FOR THE SENSITIZATION OF PARASITES TO A MEDICINAL PRODUCT | |
| EP3324983A4 (en) | METHODS AND MATERIALS FOR PRODUCING T-LYMPHOCYTES | |
| EP3365015A4 (en) | COMPOSITIONS AND METHODS FOR ANTICANCER THERAPY WITH IMMUNE MEDIATION | |
| ZA201604024B (en) | Improved feeding strategies and purification processes for monoclonal antibody production | |
| EP3556686A4 (en) | MOLDING PROCESS FOR COMPOSITE AND COMPOSITE |